Roche to Tender for 89bio at $14.50 a Share - Pegozafermin Deal Could Hit $3.5B with $6 CVR

Roche (SIX: ROG) has agreed to buy U.S. biotech 89bio (NASDAQ: ETNB) in a deal valuing the smaller company at roughly $2.4 billion upfront and as much as $3.5 billion if certain milestone payments kick in.

The headline: Roche will tender for all 89bio stock at $14.50 a share in cash and attach a non-tradeable contingent value right (CVR) that can add up to $6.00 per share if the targets are met. That CVR is what stretches the price tag toward $3.5 billion.

What Roche is buying is a late-stage candidate called pegozafermin, an FGF21 analogue being developed for metabolic dysfunction-associated steatohepatitis (MASH), the disease many people still call fatty liver. The asset sits squarely in the cardiometabolic/obesity-adjacent bucket - an area Roche has been beefing up after recent deals, including rights to a Zealand Pharma obesity therapy and the earlier purchase of Carmot's weight-loss program.

For traders, a few practical takeaways from the structure and timing: the deal is a full tender offer with a cash component, so 89bio shareholders face a clear buyout price plus the uncertainty of the CVR. The CVR's non-tradable nature means any upside tied to milestones won't be liquid until Roche honors those payments, if they happen at all.

Strategically, the move tightens Roche's footprint in cardiorenal and metabolic disease areas - an obvious play given the commercial excitement around weight-loss drugs and related metabolic therapies. Whether pegozafermin will clear the clinical and regulatory hurdles that justify the earn-outs is the open question here; FGF21 analogues have promise, but clinical success is never guaranteed.

Roche has been willing to spend big to build in this space - previous transactions ran into the billions - and this acquisition follows that pattern: targeted buys to plug gaps in late-stage development rather than greenlighting new in-house programs from scratch.

No investment direction here - just the facts: cash tender at $14.50, CVR up to $6.00, total consideration up to ~$3.5 billion, and a late-stage FGF21 program aimed at MASH. Will another big pharma follow and chase the next FGF21 winner?